Xanthogranulomatous pyelonephritis complicating crizotinib treatment of an ALK-rearranged non-small-cell lung cancer

Diagn Interv Imaging. 2018 Apr;99(4):267-268. doi: 10.1016/j.diii.2018.01.008. Epub 2018 Feb 19.
No abstract available

Keywords: Anaplastic lymphoma kinase rearrangement; Crizotinib; Lung cancer; Xanthogranulomatous pyelonephritis.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Crizotinib
  • Gene Rearrangement
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Male
  • Middle Aged
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / adverse effects*
  • Pyelonephritis, Xanthogranulomatous / chemically induced*
  • Pyrazoles / administration & dosage
  • Pyrazoles / adverse effects*
  • Pyridines / administration & dosage
  • Pyridines / adverse effects*
  • Receptor Protein-Tyrosine Kinases / genetics

Substances

  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Crizotinib
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases